Investor Report

Asieris Releases 2022 Annual Report: Make Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions

Asieris Pharmaceuticals 2022 Q3 Quarterly Report

Highlights of Asieris 2022 Semi-Annual Report

Asieris Pharmaceuticals (688176.SH) Issued 2022 Semi-Annual Report: Accelerated Global Clinical Development and Progressive Implementation of Its Integrated Diagnosis-Treatment Commercialization Strategy

Asieris Pharmaceuticals 2022 Q1 Quarterly Report

Asieris Pharmaceuticals Announces 2021 Annual Report: Steady Progress in Core Product Pipeline and Progressive Implementation of the Integrated Diagnosis and Treatment Commercialization Strategy

Asieris Receives Approval in Australia for Phase I Study of APL-2401 in Patients with FGFR2/3-Driven Advanced Solid Tumors

Asieris Pharmaceuticals Unveils 2023 Semi-Annual Report, Demonstrating Initial Success of Specialty Pharma Strategy and Multi-Product Synergistic Commercialization

Asieris Releases 2022 Annual Report: Make Steady Progress in its Clinical Development, Global Expansion to Treat Genitourinary Tumors, and Implementing its Commercialization Strategy to Provide Integrated Diagnosis-to-Treatment Solutions